|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |||
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. | SEC 1474 (9-02) |
1. Title of Derivative Security (Instr. 3) |
2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) |
6. Date Exercisable and Expiration Date (Month/Day/Year) |
7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
8. Price of Derivative Security (Instr. 5) |
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) |
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) |
11. Nature of Indirect Beneficial Ownership (Instr. 4) |
||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
Non-Qualified Stock Option (right to buy) | $ 32.07 | 02/25/2014 | X | 15,000 | 02/04/2014 | 02/04/2019 | Common Stock | 15,000 | (6) | 0 | D | ||||
Non-Qualified Stock Option (right to buy) | $ 32.31 | 02/25/2014 | X | 938 | (7) | 02/04/2020 | Common Stock | 938 | (6) | 0 | D | ||||
Non-Qualified Stock Option (right to buy) | $ 37 | 02/25/2014 | X | 1,250 | (7) | 07/21/2020 | Common Stock | 1,250 | (6) | 1,563 | D | ||||
Non-Qualified Stock Option (right to buy) | $ 43.12 | 02/25/2014 | X | 938 | (7) | 02/02/2021 | Common Stock | 938 | (6) | 3,750 | D | ||||
Non-Qualified Stock Option (right to buy) | $ 43.62 | 02/25/2014 | X | 3,571 | (7) | 07/20/2021 | Common Stock | 3,571 | (6) | 5,313 | D | ||||
Non-Qualified Stock Option (right to buy) | $ 46.53 | 02/25/2014 | X | 6,923 | (7) | 02/01/2022 | Common Stock | 6,923 | (6) | 6,924 | D |
Reporting Owner Name / Address | Relationships | |||
Director | 10% Owner | Officer | Other | |
COSTELLO RICHARD A 951 CALLE AMANECER SAN CLEMENTE, CA 92673 |
Vice President Sales |
By: Lynn DeMartini For: Richard A. Costello | 02/26/2014 | |
**Signature of Reporting Person | Date |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
(1) | The price recorded in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.27 to $58.81 inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. |
(2) | These securities are Restricted Stock Units. |
(3) | The price recorded in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.50 to $58.68 inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. |
(4) | Shares purchased through Employee Stock Purchase Plan |
(5) | The price recorded in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.49 to $58.50 inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. |
(6) | Transaction is the exercise of a derivative security; see Column 2. |
(7) | Options vest and are exercisable as to 25% of the underlying grant one year after the date of grant and in equal monthly installments thereafter for three additional years. |